MX389194B - Compuestos terapéuticos y métodos. - Google Patents

Compuestos terapéuticos y métodos.

Info

Publication number
MX389194B
MX389194B MX2018004114A MX2018004114A MX389194B MX 389194 B MX389194 B MX 389194B MX 2018004114 A MX2018004114 A MX 2018004114A MX 2018004114 A MX2018004114 A MX 2018004114A MX 389194 B MX389194 B MX 389194B
Authority
MX
Mexico
Prior art keywords
domain
methods
therapeutic compounds
compounds
engaging
Prior art date
Application number
MX2018004114A
Other languages
English (en)
Other versions
MX2018004114A (es
Inventor
Daniel Attilio Vallera
Jeffrey S Miller
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of MX2018004114A publication Critical patent/MX2018004114A/es
Publication of MX389194B publication Critical patent/MX389194B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos diseñados por ingeniería genética que se acoplan a células NK y métodos para usar los compuestos. En general, el compuesto incluye un dominio de acoplamiento a NK, un dominio de objetivo que se une selectivamente a una célula objetivo, y un dominio de activación de NK que enlaza operablemente el dominio de acoplamiento a NK y el dominio de objetivo.
MX2018004114A 2015-10-06 2016-10-06 Compuestos terapéuticos y métodos. MX389194B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562237835P 2015-10-06 2015-10-06
PCT/US2016/055722 WO2017062604A1 (en) 2015-10-06 2016-10-06 Therapeutic compounds and methods

Publications (2)

Publication Number Publication Date
MX2018004114A MX2018004114A (es) 2018-08-21
MX389194B true MX389194B (es) 2025-03-20

Family

ID=58488527

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004114A MX389194B (es) 2015-10-06 2016-10-06 Compuestos terapéuticos y métodos.

Country Status (12)

Country Link
US (4) US11098100B2 (es)
EP (2) EP4056190A1 (es)
JP (3) JP7461620B2 (es)
KR (1) KR102716215B1 (es)
CN (1) CN108697736A (es)
AU (2) AU2016336451B2 (es)
BR (1) BR112018006811A2 (es)
IL (1) IL258931B (es)
MX (1) MX389194B (es)
RU (1) RU2770001C2 (es)
SG (2) SG11201802794PA (es)
WO (1) WO2017062604A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113713091A (zh) 2015-02-06 2021-11-30 新加坡国立大学 工程免疫细胞及其用途和生产方法
BR112018006811A2 (en) 2015-10-06 2018-10-16 Regents Of The University Of Minnesota therapeutic compounds and methods
CA3016563A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3511340B1 (en) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US11648269B2 (en) 2017-08-10 2023-05-16 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019118266A1 (en) 2017-12-12 2019-06-20 Macrogenics Inc. Bispecific cd 16-binding molecules and their use in the treatment of disease
CU24545B1 (es) * 2017-12-29 2021-09-07 Ct Ingenieria Genetica Biotecnologia Péptido antagonista de la actividad de la interleucina-15
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN120535653A (zh) * 2018-10-19 2025-08-26 明尼苏达大学董事会 Nk接合子分子及其使用方法
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
CN114127112A (zh) * 2019-02-21 2022-03-01 马伦戈治疗公司 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
EP3927744A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
JP7631234B2 (ja) * 2019-05-31 2025-02-18 シティ・オブ・ホープ Ｃｄ３３陽性悪性腫瘍治療用ｃｄ３３標的化キメラ抗原受容体修飾ｔ細胞
WO2020251941A1 (en) * 2019-06-12 2020-12-17 The Board Of Trustees Of The Leland Stanford Junior University Methods to treat viral infections
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
US20220324972A1 (en) * 2019-09-16 2022-10-13 Regents Of The University Of Minnesota Immunotherapy compounds and methods
EP4041757A4 (en) * 2019-09-26 2024-04-17 Regents of the University of Minnesota VIRAL ANTIGEN BINDING NK ENGAGERS COMPOUNDS AND METHODS OF USE
WO2021138407A2 (en) * 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
WO2021216916A1 (en) 2020-04-22 2021-10-28 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins
WO2021247794A2 (en) * 2020-06-03 2021-12-09 Regents Of The University Of Minnesota B7h3-targeting proteins and methods of use thereof
WO2022150379A1 (en) * 2021-01-08 2022-07-14 Regents Of The University Of Minnesota Nk cell engager molecules and methods of use
JP2024529494A (ja) * 2021-07-30 2024-08-06 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗原ターゲティング、抗ｃｄ１６ａおよび免疫エフェクター細胞活性化の三機能性融合タンパク質ならびにその応用
WO2023036270A1 (zh) 2021-09-09 2023-03-16 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
US20250319128A1 (en) * 2022-05-16 2025-10-16 Northwestern University Il15-modified car t cells for dual targeting
US20250333445A1 (en) * 2022-05-31 2025-10-30 Oncopeptides Innovation 1 Ab Novel polypeptides
CN119998330A (zh) 2022-09-15 2025-05-13 艾维迪治疗知识产权有限公司 用于刺激nk细胞的多特异性抗原结合蛋白及其用途
WO2024064446A2 (en) * 2022-09-19 2024-03-28 Duke University Compositions and methods for the enhancement of immune cell activities against cancer
WO2024230591A1 (zh) * 2023-05-06 2024-11-14 北京新合睿恩生物医疗科技有限公司 IL-15融合蛋白及其mRNA序列和应用
WO2024235833A1 (en) * 2023-05-12 2024-11-21 Christian-Albrechts-Universität Zu Kiel Means and methods for the expansion of nk-cells
WO2025191137A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of trop2-specific antigen binding proteins and cytokines
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
CN1753692A (zh) * 2002-12-20 2006-03-29 比奥根艾迪克Ma公司 淋巴毒素β受体药剂与化疗剂的联合用药
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
EP2292264A3 (en) 2003-07-24 2012-12-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7419667B2 (en) 2004-03-19 2008-09-02 Morinaga Milk Industry Co. Ltd. Drug for cancer therapy
EP1861425B1 (en) 2005-03-10 2012-05-16 Morphotek, Inc. Anti-mesothelin antibodies
JP2010500967A (ja) 2006-07-20 2010-01-14 ザ ジェネラル ホスピタル コーポレイション コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット
US20100055724A1 (en) 2007-01-26 2010-03-04 University Of Louisville Research Foundation, Inc. Methods of detecting autoantibodies for diagnosing and characterizing disorders
US9155798B2 (en) 2007-08-24 2015-10-13 Regents Of The University Of Minnesota Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agents
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012017522A1 (ja) 2010-08-03 2012-02-09 富士通株式会社 検証プログラムおよび検証装置
EP3851459B1 (en) * 2010-09-21 2024-05-01 Altor BioScience, LLC Multimeric il-15 soluble fusion molecules and methods of making and using same
CN102251013A (zh) 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
EP3954704A1 (en) * 2011-06-03 2022-02-16 XOMA Technology Ltd. Antibodies specific for tgf-beta
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
AU2012309824A1 (en) * 2011-09-12 2013-04-18 Abbvie Biotherapeutics Inc. Artificial NK cells and uses thereof
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
US9258177B2 (en) * 2012-08-02 2016-02-09 International Business Machines Corporation Storing a data stream in a set of storage devices
US20160015749A1 (en) * 2013-03-05 2016-01-21 Baylor College Of Medicine Engager cells for immunotherapy
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
EP4420663A3 (en) * 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
BR112018006811A2 (en) 2015-10-06 2018-10-16 Regents Of The University Of Minnesota therapeutic compounds and methods

Also Published As

Publication number Publication date
RU2770001C2 (ru) 2022-04-14
EP3359168A4 (en) 2019-08-07
EP4056190A1 (en) 2022-09-14
JP7555625B2 (ja) 2024-09-25
MX2018004114A (es) 2018-08-21
AU2016336451A1 (en) 2018-04-26
RU2018116565A3 (es) 2020-11-03
JP2023089290A (ja) 2023-06-27
US20200148737A1 (en) 2020-05-14
KR102716215B1 (ko) 2024-10-10
BR112018006811A2 (en) 2018-10-16
US20210395326A1 (en) 2021-12-23
AU2016336451B2 (en) 2023-06-29
JP2022037037A (ja) 2022-03-08
SG11201802794PA (en) 2018-05-30
IL258931B (en) 2022-09-01
JP7461620B2 (ja) 2024-04-04
US11098100B2 (en) 2021-08-24
JP2018531939A (ja) 2018-11-01
EP3359168A1 (en) 2018-08-15
JP7274781B2 (ja) 2023-05-17
WO2017062604A1 (en) 2017-04-13
CN108697736A (zh) 2018-10-23
CA3001185A1 (en) 2017-04-13
IL258931A (en) 2018-06-28
AU2023233318A1 (en) 2023-10-12
SG10201912792YA (en) 2020-02-27
US20200087369A1 (en) 2020-03-19
US20180282386A1 (en) 2018-10-04
RU2018116565A (ru) 2019-11-07
KR20180057715A (ko) 2018-05-30
US11098101B2 (en) 2021-08-24

Similar Documents

Publication Publication Date Title
MX389194B (es) Compuestos terapéuticos y métodos.
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201891211A1 (ru) Ингибиторы cxcr2
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
MX377710B (es) Anticuerpos monoclonales contra bcma.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
EP3310154A4 (en) PLANTS WITH INCREASED TOLERANCE AGAINST HERBICIDES
EA201591615A1 (ru) Замещенные ксантины и способы их применения
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA201691991A1 (ru) Мультиспецифические антитела
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MX375786B (es) Biosintesis microbiana de ergotioneina.
AR101905A1 (es) Compuestos bicíclicos
DK3105190T3 (da) Behandling af tilbagediffusion af grundvandsmagasinmatrix
NZ780072A (en) Glycotargeting therapeutics
MX385788B (es) Método de tratamiento con tradipitant.
CL2015002358A1 (es) Compuestos bicíclicos.
CL2016001488A1 (es) Quinazolin-thf-aminas como inhibidores de pde1
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EP3484278A4 (en) PLANTS WITH GREATER TOLERANCE AGAINST HERBICIDES
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.